Share

October 2019; 5 (5) ArticleOpen Access

Epidemiology of DYT1 dystonia

Estimating prevalence via genetic ascertainment

Joseph Park, Scott M. Damrauer, Aris Baras, Jeffrey G. Reid, John D. Overton, Pedro Gonzalez-Alegre
First published September 13, 2019, DOI: https://doi.org/10.1212/NXG.0000000000000358
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
790

Share

Article Information

vol. 5 no. 5 e358
DOI: 
https://doi.org/10.1212/NXG.0000000000000358
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2376-7839
History: 
  • Received June 4, 2019
  • Accepted in final form August 2, 2019
  • First Published September 13, 2019.
Copyright & Usage: 
Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Joseph Park, AB,
    2. Scott M. Damrauer, MD,
    3. Aris Baras, MD, MBA,
    4. Jeffrey G. Reid, PhD,
    5. John D. Overton, PhD and
    6. Pedro Gonzalez-Alegre, MD, PhD
  1. Joseph Park, AB,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. National Human Genome Research Institute (NHGRI) of the National Institutes of Health, Award Number F30HG010442, 2019- 2022

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Scott M. Damrauer, MD,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. (1) Novel targets for therapeutic manipulation to treat HDL-C, triglycerides and coronary disease and (2) novel targets for therapeutic manipulation to treat abdominal aortic aneurysms

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Spouse consulting for Rhythm Pharmaceuticals; (2) Spouse consulting for Reata

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) RenalytixAI, (2) CytoVas, LLC

    Research Support, Government Entities:

    1. (1) U.S. Department of Veterans Affairs, Clinical Science Research and Development, IK2-CX00178-01, PI, 2018-current, (2) National Heart Lung Blood Institute, 1RO1HL138306-01A1, co-investigator, 2018-current; (3) U.S. Department of Veterans Affairs, Basic Science Research and Development, BX- 003362-62, co-investigator, 2017-current.

    Research Support, Academic Entities:

    1. (1) Vanderbilt University (2) Partners Healthcare

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Aris Baras, MD, MBA,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Jeffrey G. Reid, PhD,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. Regeneron Pharmaceuticals, VP Genome Informatics, 6

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Regeneron Pharmaceuticals

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. Regeneron Pharmaceuticals

    Legal Proceedings:

    1. NONE

  5. John D. Overton, PhD and
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. Regeneron Genetics Center, Vice President and Head of Sequencing and Lab Operations, 6 years

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Regeneron Genetics Center/Regeneron Pharmaceuticals

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. Regeneron Pharmaceuticals

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Pedro Gonzalez-Alegre, MD, PhD
    7. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. - American Academy of Neurology: honoraria as a speaker in Annual Meeting 2017 - Movement Disorders Society (Pan American Section): honoraria as a speaker in School for Young Neurologists 2017

    Editorial Boards:

    1. Academic Editor, PLoS One

    Patents:

    1. Patent on Allele-Specific Silencing for disease genes. Based on RNA interference. Licensed by the University of Iowa to Spark Therapeutics

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. - Consulting for Spark Therapeutics (contract pending execution) - Consulting for SAGE Therapeutics (contract pending execution)

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. I received research grants from the US Department of Defense and the NIH/NINDS unrelated to this work.

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Research Grant for the Dystonia Medical Research Foundation Research Grant from the Clinical Consortium for X-linked Dystonia Parkinsonism

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License fee payments, Technology or Inventions:

    1. Licensing fees from Spark Therapeutics for

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Medicine (J.P.), University of Pennsylvania, Philadelphia; Department of Surgery (S.M.D.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Regeneron Genetics Center (A.B., J.G.R., J.D.O.), Tarrytown, NY; and Department of Neurology (P.G.-A.), Perelman School of Medicine, University of Pennsylvania, Philadelphia.
  1. Correspondence
    Dr. Gonzalez-Alegre pedro.gonzalez-alegre{at}uphs.upenn.edu

Article usage

Article usage: September 2019 to October 2023

AbstractFullPdfSource
Sep 2019822427Highwire
Oct 201912324880Highwire
Nov 20192125738Highwire
Dec 2019658629Highwire
Jan 202046021Highwire
Feb 202026810Highwire
Mar 202076911Highwire
Apr 202026625Highwire
May 2020210017Highwire
Jun 2020512016Highwire
Jul 202007119Highwire
Aug 202017117Highwire
Sep 202088526Highwire
Oct 202028515Highwire
Nov 202028813Highwire
Dec 202046513Highwire
Jan 202139514Highwire
Feb 202139015Highwire
Mar 202118315Highwire
Apr 20211658Highwire
May 20215848Highwire
Jun 20210718Highwire
Jul 2021317530Highwire
Aug 20211475Highwire
Sep 20212536Highwire
Oct 202157026Highwire
Nov 202113617Highwire
Dec 202113913Highwire
Jan 20223384Highwire
Feb 20221509Highwire
Mar 202238714Highwire
Apr 20220569Highwire
May 202245014Highwire
Jun 202215413Highwire
Jul 202224110Highwire
Aug 20221488Highwire
Sep 202235717Highwire
Oct 202227514Highwire
Nov 2022711825Highwire
Dec 202224111Highwire
Jan 20233779Highwire
Feb 202356410Highwire
Mar 20232466Highwire
Apr 20233526Highwire
May 202324113Highwire
Jun 20232409Highwire
Jul 20234508Highwire
Aug 202304710Highwire
Sep 202304717Highwire
Oct 202323912Highwire

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. [email protected]
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me

Recommended articles